CIC
RCUS icon

Cornercap Investment Counsel’s Arcus Biosciences RCUS Stock Holding History

Cornercap Investment Counsel’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,712
Closed -$194K – 625
2024
Q2 		$194K Sell
12,712
-105
-0.8% -$1.7K 0.03% 544
2024
Q1 		$242K Buy
12,817
+30
+0.2% +$519 0.04% 542
2023
Q4 		$244K Hold
12,787
– – 0.04% 508
2023
Q3 		$230K Sell
12,787
-98
-0.8% -$1.97K 0.04% 480
2023
Q2 		$262K Buy
12,885
+506
+4% +$9.63K 0.05% 474
2023
Q1 		$226K Buy
+12,379
New +$237K 0.04% 489
2022
Q4 		– Sell
-8,138
Closed -$213K – 634
2022
Q3 		$213K Buy
+8,138
New +$215K 0.04% 488

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cornercap Investment Counsel's RCUS Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 12,712 shares — an estimated $194K sold.

Cornercap Investment Counsel first reported a position in RCUS in Q3 2022 and held it in 7 quarters. The position peaked at $262K in Q2 2023. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 12,712 Arcus Biosciences shares in Q3 2024, an estimated $194K.
  • Cornercap Investment Counsel first reported a position in Arcus Biosciences in Q3 2022 and held it in 7 quarters.
  • Cornercap Investment Counsel's Arcus Biosciences position peaked at $262K in Q2 2023.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.